Unknown

Dataset Information

0

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.

ABSTRACT: We describe here the existence of a heregulin-HER3 autocrine loop, and the contribution of heregulin-dependent, HER2-mediated HER3 activation to gefitinib insensitivity in non-small cell lung cancer (NSCLC). ADAM17 protein, a major ErbB ligand sheddase, is upregulated in NSCLC and is required not only for heregulin-dependent HER3 signaling, but also for EGFR ligand-dependent signaling in NSCLC cell lines. A selective ADAM inhibitor, INCB3619, prevents the processing and activation of multiple ErbB ligands, including heregulin. In addition, INCB3619 inhibits gefitinib-resistant HER3 signaling and enhances gefitinib inhibition of EGFR signaling in NSCLC. These results show that ADAM inhibition affects multiple ErbB pathways in NSCLC and thus offers an excellent opportunity for pharmacological intervention, either alone or in combination with other drugs.

SUBMITTER: Zhou BB 

PROVIDER: S-EPMC4451119 | biostudies-literature | 2006 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

We describe here the existence of a heregulin-HER3 autocrine loop, and the contribution of heregulin-dependent, HER2-mediated HER3 activation to gefitinib insensitivity in non-small cell lung cancer (NSCLC). ADAM17 protein, a major ErbB ligand sheddase, is upregulated in NSCLC and is required not only for heregulin-dependent HER3 signaling, but also for EGFR ligand-dependent signaling in NSCLC cell lines. A selective ADAM inhibitor, INCB3619, prevents the processing and activation of multiple Er  ...[more]

Similar Datasets

Unknown The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
| S-EPMC4741788 | biostudies-literature
Unknown Development of small molecules targeting the pseudokinase Her3.
| S-EPMC4633287 | biostudies-literature
Unknown EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients.
| S-EPMC6520391 | biostudies-literature
Unknown Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma.
| S-EPMC3822432 | biostudies-literature
Unknown Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.
| S-EPMC7254871 | biostudies-literature
Unknown Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.
| S-EPMC7563838 | biostudies-literature
Unknown Targeting PKC?-PAK1 in EGFR-mutation positive non-small cell lung cancer.
| S-EPMC6835115 | biostudies-literature
Unknown Targeting EGFR and PI3K pathways in ovarian cancer.
| S-EPMC3790180 | biostudies-other
Unknown Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.
| S-EPMC4823091 | biostudies-literature
Unknown Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
| S-EPMC6742540 | biostudies-literature